Does mutated K-RAS oncogene attenuate the effect of Sulindac in colon cancer chemoprevention?

The non-steroidal anti-inflammatory drug (NSAID) Sulindac has been successfully used alone or in combination with other agents to suppress colon tumorigenesis in patients with genetic predisposition, and also showed its efficacy in prevention of sporadic colon adenomas. At the same time, some experi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Prev Res (Phila)
Päätekijät: Rice, Photini FS., Ehrichs, Kevin G., Jones, Mykella S., Chen, Hwudarw, Hsu, Chiu-Hsieh, Abril, Edward R., Nagle, Raymond B., Besselsen, David G., Barton, Jennifer K., Ignatenko, Natalia A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7733710/
https://ncbi.nlm.nih.gov/pubmed/29118162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-17-0230
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia